Profiles of Medicaid Beneficiaries with Treatment-Resistant Depression Initiated on Esketamine Nasal Spray
Medicaid beneficiaries with TRD who initiated esketamine treatment had a high comorbidity burden and a higher proportion of racial minorities than the US population overall. Nonetheless, most patients progressed to maintenance phase of esketamine treatment. Findings suggest that esketamine may be a viable treatment option for this complex patient population.
Authors
- Arthur Voegel
- Maryia Zhdanava (ORCID: https://orcid.org/0000-0002-7995-2578)
- Hannah E. Bowrey (ORCID: https://orcid.org/0000-0002-3774-4201)
- Anabelle Tardif‐Samson (ORCID: https://orcid.org/0009-0009-5118-1909)
- Amanda Teeple
- Kristin K. Clemens (ORCID: https://orcid.org/0000-0001-9636-5597)
- Kruti Joshi (ORCID: https://orcid.org/0000-0001-9263-5158)
- Aditi Shah
- Dominic Pilon (ORCID: https://orcid.org/0000-0002-6093-7167)
Institutions
- The University of Sydney (AU)
- Johnson & Johnson (United States) (US)
- Health Solutions (Sweden) (SE)
- Group for Research in Decision Analysis (CA)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1007/s40120-025-00802-1
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Janssen Biotech